AKT1 and osteosarcoma: Molecules such as Schisandrin B (Sch B), Budding uninhibited by benzimidazoles 1 (BUB1), can affect the malignant phenotype of osteosarcoma by activating or inhibiting the PI3K/AKT pathway (100, 101).